Clarus Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Clarus Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,666	Closed	-$237K	–	139
2023 Q1	$237K	Buy	+1,666	New	+$216K	0.15%	107
2021 Q2	–	Sell	-3,666	Closed	-$259K	–	131
2021 Q1	$259K	Hold	3,666	–	–	0.16%	108
2020 Q4	$329K	Hold	3,666	–	–	0.22%	93
2020 Q3	$511K	Hold	3,666	–	–	0.4%	53
2020 Q2	$601K	Hold	3,666	–	–	0.51%	39
2020 Q1	$343K	Sell	3,666 -200	-5%	-$22.9K	0.34%	82
2019 Q4	$509K	Hold	3,866	–	–	0.34%	81
2019 Q3	$291K	Buy	3,866 +2,050	+113%	+$242K	0.21%	97
2019 Q2	$276K	Buy	1,816 +150	+9%	+$18.2K	0.2%	82
2019 Q1	$199K	Hold	1,666	–	–	0.15%	101
2018 Q4	$182K	Hold	1,666	–	–	0.29%	91
2018 Q3	$269K	Sell	1,666 -12	-0.7%	-$1.64K	0.18%	82
2018 Q2	$124K	Buy	+1,678	New	+$158K	0.09%	173

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clarus Wealth Advisors's SRPT Position: Q2 2023 in Review

Clarus Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 1,666 shares — an estimated $237K sold.

Clarus Wealth Advisors first reported a position in SRPT in Q2 2018 and held it in 13 quarters. The position peaked at $601K in Q2 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Clarus Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Clarus Wealth Advisors sold 1,666 Sarepta Therapeutics shares in Q2 2023, an estimated $237K.
Clarus Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 13 quarters.
Clarus Wealth Advisors's Sarepta Therapeutics position peaked at $601K in Q2 2020.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Clarus Wealth Advisors's 13F filing for Q2 2023, filed 10 Jul 2023.